Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Snowflake Inc (SNOW) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Snowflake Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.99 (market cap $4.49B), while Snowflake Inc trades at $259.76 (market cap $91.07B). The key difference: Snowflake Inc is far larger — about 20.3× ACADIA Pharmaceuticals Inc.'s market cap, and Snowflake Inc is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | SNOW | |
|---|---|---|
Market Cap | $4.49B | $91.07B |
Sector | Health | Technology |
52-Week High | $28.06 | $280.16 |
52-Week Low | $20.06 | $121.11 |
Enterprise Value | $3.69B | $90.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
SNOW trades at $262.74, up 1.0% today, with a bullish technical outlook from moving averages and strong analyst consensus. The stock shows accelerating revenue growth, reaching $3.63B in 2025, but remains unprofitable with a net income margin of -23.79%. Recent news highlights AI Data Cloud traction and partnerships driving optimism, while cash flow from operations improved to $959.76M.
Outlook is positive due to AI-driven growth and consistent earnings beats, but high valuation (P/S 17.74) and persistent losses pose risks. Wall Street's $294.31 price target suggests ~12% upside, though competition and execution challenges require monitoring for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
